Welichem Biotech Inc. granted Australian Patent for compounds treating autoimmune/inflammatory diseases
A total of 16 claims covering novel compounds, pharmaceutical composition and use were granted with a term lasting to December 2019. This is the first patent issued for the Company's WBI-1000 series of compounds in a cluster of national applications pending in jurisdictions including Australia, Canada, China, Europe, Japan, Korea and the United States.
"This latest patent strengthens the Company's growing proprietary position in pre-targeted therapies that seek to address unmet medical needs in inflammatory/autoimmune diseases," said John Webster, President & CEO of Welichem. "It also provides intellectual property protection for our lead product, WBI-1001, part of a group of pharmaceutical compounds from symbiotic organisms that have great potential to treat a number of diseases and disorders," he added. The Company currently plans to begin formal clinical testing of the drug in early 2006.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.